Ex-OpenAI AI-for-Science Lead Kevin Weil Raises $215 Million to Launch AI Drug Development Startup Warp Sciences
Key Takeaways
- •Warp Sciences, a new startup founded by former OpenAI executive Kevin Weil, raised $215 million in a round led by Lightspeed Venture Partners that values the company at $865 million.
- •The company will use AI and robotics to automate lead optimization, the early drug development stage in which many variants of a promising molecule are produced and tested to improve effectiveness and limit side effects.
- •Lead optimization has traditionally been handled by Chinese firms, including WuXi AppTec, and rising US-China tensions along with pharmaceutical companies' intellectual property concerns are driving demand for alternatives.
- •The proposed BIOSECURE Act, which would restrict federal agencies from contracting with named Chinese biotechnology suppliers, could further shape demand for US-based services like Warp's.
- •Warp joins other well-funded companies, such as Recursion Pharmaceuticals and Insitro, in pairing AI systems with automated laboratories to speed up the design-build-test cycle of drug discovery.
Kevin Weil, the former head of artificial intelligence for science at OpenAI, is launching Warp Sciences, a startup that has raised $215 million to automate a key stage of drug development using AI.
The financing was led by Lightspeed Venture Partners, with participation from IVP, Premji Invest and Lux Capital. The round values Warp Sciences at $865 million after the investment, and the startup's angel backers include executives and founders from OpenAI, Coinbase, Palantir and LinkedIn.
Warp is targeting the process of producing and testing hundreds or thousands of variants of a promising molecule — a stage known in the industry as lead optimization — to improve a compound's potential effectiveness and limit harmful side effects. Lead optimization sits early in the drug development pipeline, before preclinical testing and clinical trials, and it has traditionally been handled by Chinese firms, including WuXi AppTec, one of the world's largest pharmaceutical contract development and manufacturing organizations.
Rising tensions between the United States and China, combined with pharmaceutical companies' concerns over intellectual property, have created demand for alternatives to Chinese suppliers. US lawmakers have in recent also weighed measures such as the proposed BIOSECURE Act, which would restrict federal agencies from contracting with named Chinese biotechnology suppliers, including WuXi AppTec.
Warp aims to bring this work back to the United States through a fully automated laboratory that uses robotics and experimental data to train AI models.
Weil previously served as OpenAI's chief product officer before leading the company's AI-for-science efforts. AI has become an increasingly prominent tool in pharmaceutical research, with model-driven approaches now applied across tasks ranging from molecule design to experiment planning, and a number of well-funded companies are pairing AI systems with automated laboratories to accelerate the design-build-test cycle of drug discovery — among them Recursion Pharmaceuticals and Insitro. For the field, the developments to watch include whether measures such as the BIOSECURE Act advance in Congress and Warp's progress in standing up its fully automated laboratory.
